ArticleVeterinary research2025
Construction of a replication-defective recombinant virus and cell-based vaccine for H9N2 avian influenza virus.
Article in Veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The H9N2 subtype of avian influenza is highly contagious, and although it is classified as a low-pathogenic avian influenza virus, its tendency to recombine with other subtypes of avian influenza viruses has made it a potential problem for the poultry industry. Vaccines currently used to prevent this disease are all inactivated, making it difficult to stimulate long-lasting immunity, and have a very weak ability to trigger cellular immunity, thus failing to address the problem of virus shedding. Live-attenuated vaccines are capable of stimulating cellular immunity but carry the risk of recombination with wild-type strains. In this study, we successfully rescued a replication-deficient H9N2 strain (H9-SD18GD12HA) using reverse genetic techniques, which was obtained by replacing the neuraminidase (NA) gene with the open reading frame of the hemagglutinin (HA) gene with the PR8 strain as the backbone. Dynamic growth results showed that H9-SD18GD12HA can proliferate only under NA-containing conditions and therefore cannot grow in normal animals or cells. After immunization of chickens with H9-SD18GD12HA using eye and nose drops, both humoral and cellular immunity were stimulated, and some degree of reduction in virus shedding was observed. These results indicate that H9-SD18GD12HA has good immunogenicity, does not proliferate in vivo, and has the potential to be developed into a novel live-attenuated vaccine for the H9N2 subtype of avian influenza.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.